Funding for Massachusetts Startups Slower, but Still Strong, in August; Early-Stage Deals Predominate
The pace of everything in Massachusetts seems to slow in August, and startup financings were not an exception this year. But despite the tail off from July’s big deal-making surge, investments in Bay State startups looked pretty good last month. All told, VCs pumped $179.2 million into 21 deals, according to data provided to Xconomy by ChubbyBrain, a New York-based information services company developing tools for investors, startups, and aspiring entrepreneurs. And while the August tally was below the $215 million and 25 deals seen in July, it was nicely above June’s total of $139.5 million invested in 15 deals—and has to be seen as more evidence that the economy is on the rebound.
The biggest venture deal of the month was a $29 million Series D round for Gloucester Pharmaceuticals. The money came at a great time for the cancer drug developer and its investors: in early September, just a few weeks after the round closed, Gloucester’s drug for cutaneous T-cell lymphoma, romidepsin, was recommended for approval by the FDA’s cancer drug panel. A bit behind Gloucester in deal size was MIT Media Lab spinout iWalk, which took in $20 million in a Series B round. iWalk is developing an actively powered prosthetic ankle and foot. The stars also aligned for Constellation Pharmaceuticals, which had the month’s third biggest deal, a $17.2 million Series A-II infusion. All three companies are based in Cambridge.
You can find a table of all August Bay State venture deals on the second page of this post. There was only one debt financing deal in the month, a $360,000ish deal for BigBad, a Boston web development company. That compared to four debt financings last month.
Other highlights from the August ChubbyBrain data:
—The 21 venture investments ran the gamut from early- to late-stage deals, but once again the majority involved earlier rounds, with one seed stage deal, six Series A financings, and … Next Page »